Abstract Library

#4646 Dysregulated miRNA in patients with GEP-NEN and potential role as circulating biomarker

Introduction: Neuroendocrine neoplasms (NENs) are a class of rare and molecularly extremely heterogeneous tumours. NENs arise predominantly in the gastrointestinal (GEP) and pulmonary tracts but can also involve thyroid and breast. NENs often present with non-specific symptoms and lack early specific biomarkers, leading to frequent metastatic diagnoses and primary site challenges.

Conference:

Presenting Author:

Authors: Di Mauro A, Clemente O, Cannella L, Della Vittoria G, Neri G,

Keywords: neuroendocrine tumour, miRNome profiling, biomarker, gep-net, molecular biology,

#4330 Clinical and gut microbiota (GM) markers of aggressive carcinoid syndrome (CS)

Introduction: While most patients (pts) with CS present indolent disease (iCS), others have aggressive disease (aCS). Little is known about biomarkers of aCS.

Conference:

Presenting Author: Riechelmann R

Authors: Riechelmann R, Henrique K, Durant L, Iebba V, Derosa L,

Keywords: neuroendocrine tumour, carcinoid syndrome, gut microbiome,

#4289 Temozolomide-associated hypermutation and response to immunotherapy in advanced pulmonary neuroendocrine tumours

Introduction: Temozolomide (TMZ) cytotoxicity depends on an intact DNA mismatch repair (MMR) pathway and low levels of O6-methylguanine DNA methyltransferase (MGMT). However, absence of MGMT-mediated repair coupled with defective MMR (dMMR) may lead to enrichment of C:G to A:T transitions throughout the genome, a marked increase in tumour mutational burden (TMB), and loss of TMZ-induced cytotoxicity. This resistance mechanism is called TMZ-associated hypermutation (TAH). Theoretically, this effect could lead to sensitivity to checkpoint inhibitor immunotherapy.

Conference:

Presenting Author: Buikhuisen W

Authors: Buikhuisen W, Badrising S, Moonen L, Derks J, Monkhorst K,

Keywords: Pulmonary NET, whole genome sequencing, temozolomide signature, immunotherapy,

#4128 Validation of a 3-gene signature of response to axitinib in patients with advanced NETs

Introduction: Axitinib in combination with SSA significantly improved ORR and PFS per central blinded radiological assessment, as compared to placebo and SSA in 253 EP-NETs in the AXINET trial. The magnitude of the benefit, however, was limited. We recently described a 3-gene tumor transcriptomic signature predictive of response to axitinib in NET patients.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Carretero-Puche C, Antón-Pascual B, Capdevila J, Benavent M,

Keywords: axitinib, sunitinib, tyrosine kinase inhibitor, predictive biomarker, signature, elisa,

#4127 A CT-based radiomics and deep learning signature for evaluating the somatostatin receptor 2 in non-functional pancreatic neuroendocrine tumors: A multicohort, retrospective study

Introduction: The diagnosis and treatment of Non-functional Pancreatic Neuroendocrine Tumor (NF-panNET) with unlabeled or labeled somatostatin analogues necessitate high expression of the somatostatin receptor subtype 2 (SSTR2), typically identified using PET or SPECT imaging. However, the application of PET or SPECT imaging is limited due to its low spatial resolution and unavailability in all units.

Conference:

Presenting Author:

Authors: Tang W, Wenchao G, Yinli C, Jie C,

Keywords: Non-functional Pancreatic Neuroendocrine Tumor, SSTR2, Radiomics, Deep-learning, CT,